|
1
|
Castillo-Martin M, Domingo-Domenech J,
Karni-Schmidt O, Matos T and Cordon-Cardo C: Molecular pathways of
urothelial development and bladder tumorigenesis. Urol Oncol.
28:401–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alessi DR, James SR, Downes CP, et al:
Characterization of a 3-phosphoinositide-dependent protein kinase
which phosphorylates and activates protein kinase B alpha. Curr
Biol. 7:261–269. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000.PubMed/NCBI
|
|
6
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu W and Neckers L: Targeting the
molecular chaperone heat shock protein 90 provides a multifaceted
effect on diverse cell signaling pathways of cancer cells. Clin
Cancer Res. 13:1625–1629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Millson SH, Truman AW, Racz A, et al:
Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms
of human Hsp90 differ with regard to their capacities for
activation of certain client proteins, whereas only Hsp90beta
generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J.
274:4453–4463. 2007. View Article : Google Scholar
|
|
9
|
Solit DB, Ivy SP, Kopil C, et al: Phase I
trial of 17-allylamino-17-demethoxygeldanamycin in patients with
advanced cancer. Clin Cancer Res. 13:1775–1782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Basso AD, Solit DB, Chiosis G, Giri B,
Tsichlis P and Rosen N: Akt forms an intracellular complex with
heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by
inhibitors of Hsp90 function. J Biol Chem. 277:39858–39866. 2002.
View Article : Google Scholar
|
|
11
|
Bonifati V, Rizzu P, Squitieri F, et al:
DJ-1 (PARK7), a novel gene for autosomal recessive, early onset
parkinsonism. Neurol Sci. 24:159–160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taira T, Saito Y, Niki T, Iguchi-Ariga SM,
Takahashi K and Ariga H: DJ-1 has a role in antioxidative stress to
prevent cell death. EMBO Rep. 5:213–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim RH, Peters M, Jang Y, et al: DJ-1, a
novel regulator of the tumor suppressor PTEN. Cancer Cell.
7:263–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuen HF, Chan YP, Law S, et al: DJ-1 could
predict worse prognosis in esophageal squamous cell carcinoma.
Cancer Epidemiol Biomarkers Prev. 17:3593–3602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le Naour F, Misek DE, Krause MC, et al:
Proteomics-based identification of RS/DJ-1 as a novel circulating
tumor antigen in breast cancer. Clin Cancer Res. 7:3328–3335.
2001.PubMed/NCBI
|
|
16
|
Tian M, Cui YZ, Song GH, et al: Proteomic
analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins
in pancreatic juice from pancreatic ductal adenocarcinoma patients.
BMC Cancer. 8:2412008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Knowles MA, Platt FM, Ross RL and Hurst
CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in
bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Askham JM, Platt F, Chambers PA, Snowden
H, Taylor CF and Knowles MA: AKT1 mutations in bladder cancer:
identification of a novel oncogenic mutation that can co-operate
with E17K. Oncogene. 29:150–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lebret T, Watson RW, Molinie V, et al:
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in
bladder carcinoma. Cancer. 98:970–977. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cardillo MR, Sale P and Di Silverio F:
Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer
Res. 20:4579–4583. 2000.PubMed/NCBI
|
|
21
|
Ebele JN, Sauter G, Epstein JI and
Sesterhenn IA; World Health Organization. Classification of Tumors.
Pathology and Genetics of Tumours of the Urinary System and Male
Genital Organs. IARC Press; Lyon: 2004
|
|
22
|
Fan J, Ren H, Jia N, et al: DJ-1 decreases
Bax expression through repressing p53 transcriptional activity. J
Biol Chem. 283:4022–4030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clements CM, McNally RS, Conti BJ, Mak TW
and Ting JP: DJ-1, a cancer- and Parkinson's disease-associated
protein, stabilizes the antioxidant transcriptional master
regulator Nrf2. Proc Natl Acad Sci USA. 103:15091–15096. 2006.
|
|
24
|
Zhu XL, Wang ZF, Lei WB, Zhuang HW, Jiang
HY and Wen WP: DJ-1: A novel independent prognostic marker for
survival in glottic squamous cell carcinoma. Cancer Sci.
101:1320–1325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Puzio-Kuter AM, Castillo-Martin M, Kinkade
CW, et al: Inactivation of p53 and Pten promotes invasive bladder
cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harris LD, De La Cerda J, Tuziak T, et al:
Analysis of the expression of biomarkers in urinary bladder cancer
using a tissue microarray. Mol Carcinog. 47:678–685. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schultz L, Albadine R, Hicks J, et al:
Expression status and prognostic significance of mammalian target
of rapamycin pathway members in urothelial carcinoma of urinary
bladder after cystectomy. Cancer. 116:5517–5526. 2010. View Article : Google Scholar
|
|
28
|
Lopez-Knowles E, Hernandez S, Malats N, et
al: PIK3CA mutations are an early genetic alteration associated
with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401–7404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Platt FM, Hurst CD, Taylor CF, Gregory WM,
Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase
pathway gene alterations in bladder cancer. Clin Cancer Res.
15:6008–6017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian CN, Furge KA, Knol J, et al:
Activation of the PI3K/AKT pathway induces urothelial carcinoma of
the renal pelvis: identification in human tumors and confirmation
in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pantuck AJ, Seligson DB, Klatte T, et al:
Prognostic relevance of the mTOR pathway in renal cell carcinoma:
implications for molecular patient selection for targeted therapy.
Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
King JC, Xu J, Wongvipat J, et al:
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in
prostate oncogenesis. Nat Genet. 41:524–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H
and Yuan J: Pten deficiency activates distinct downstream signaling
pathways in a tissue-specific manner. Cancer Res. 66:1929–1939.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramanathan RK, Egorin MJ, Erlichman C, et
al: Phase I pharmacokinetic and pharmacodynamic study of
17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor
of heat-shock protein 90, in patients with advanced solid tumors. J
Clin Oncol. 28:1520–1526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Modi S, Stopeck A, Linden H, et al: HSP90
inhibition is effective in breast cancer: a phase II trial of
tanespimycin (17-AAG) plus trastuzumab in patients with
HER2-positive metastatic breast cancer progressing on trastuzumab.
Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pacey S, Wilson RH, Walton M, et al: A
phase I study of the heat shock protein 90 inhibitor alvespimycin
(17-DMAG) given intravenously to patients with advanced solid
tumors. Clin Cancer Res. 17:1561–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karkoulis PK, Stravopodis DJ, Margaritis
LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces
downregulation of critical Hsp90 protein clients and results in
cell cycle arrest and apoptosis of human urinary bladder cancer
cells. BMC Cancer. 10:4812010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li CF, Huang WW, Wu JM, et al: Heat shock
protein 90 overexpression independently predicts inferior
disease-free survival with differential expression of the alpha and
beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res.
14:7822–7831. 2008. View Article : Google Scholar
|
|
39
|
Yang Y, Gehrke S, Haque ME, et al:
Inactivation of Drosophila DJ-1 leads to impairments of
oxidative stress response and phosphatidylinositol 3-kinase/Akt
signaling. Proc Natl Acad Sci USA. 102:13670–13675. 2005.PubMed/NCBI
|
|
40
|
Georgescu MM: PTEN tumor suppressor
network in PI3K-Akt pathway control. Genes Cancer. 1:1170–1177.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
